Prelude Therapeutics Stock Market Value
| PRLD Stock | USD 0.74 0.01 0.68% |
| Symbol | Prelude |
Prelude Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Prelude Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prelude Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prelude Therapeutics.
| 12/15/2024 |
| 03/15/2025 |
If you would invest 0.00 in Prelude Therapeutics on December 15, 2024 and sell it all today you would earn a total of 0.00 from holding Prelude Therapeutics or generate 0.0% return on investment in Prelude Therapeutics over 90 days. Prelude Therapeutics is related to or competes with Foghorn Therapeutics, Shattuck Labs, Monte Rosa, Kymera Therapeutics, Nurix Therapeutics, C4 Therapeutics, and Rezolute. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development... More
Prelude Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prelude Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prelude Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0038 | |||
| Maximum Drawdown | 61.66 | |||
| Value At Risk | (9.70) | |||
| Potential Upside | 12.5 |
Prelude Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prelude Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prelude Therapeutics' standard deviation. In reality, there are many statistical measures that can use Prelude Therapeutics historical prices to predict the future Prelude Therapeutics' volatility.| Risk Adjusted Performance | (0.0007) | |||
| Jensen Alpha | 0.2258 | |||
| Total Risk Alpha | 1.34 | |||
| Treynor Ratio | (0.05) |
Prelude Therapeutics Backtested Returns
At this point, Prelude Therapeutics is extremely dangerous. Prelude Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Prelude Therapeutics, which you can use to evaluate the volatility of the company. Please check Prelude Therapeutics' Variance of 73.75, risk adjusted performance of (0.0007), and Coefficient Of Variation of (8,654) to confirm if the risk estimate we provide is consistent with the expected return of 7.0E-4%. The company holds a Beta of 2.36, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prelude Therapeutics will likely underperform. Prelude Therapeutics right now holds a risk of 8.65%. Please check Prelude Therapeutics treynor ratio and the relationship between the skewness and price action indicator , to decide if Prelude Therapeutics will be following its historical price patterns.
Auto-correlation | -0.05 |
Very weak reverse predictability
Prelude Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Prelude Therapeutics time series from 15th of December 2024 to 29th of January 2025 and 29th of January 2025 to 15th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prelude Therapeutics price movement. The serial correlation of -0.05 indicates that only as little as 5.0% of current Prelude Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.05 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Prelude Therapeutics lagged returns against current returns
Autocorrelation, which is Prelude Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Prelude Therapeutics' stock expected returns. We can calculate the autocorrelation of Prelude Therapeutics returns to help us make a trade decision. For example, suppose you find that Prelude Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Prelude Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Prelude Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Prelude Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Prelude Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Prelude Therapeutics Lagged Returns
When evaluating Prelude Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Prelude Therapeutics stock have on its future price. Prelude Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Prelude Therapeutics autocorrelation shows the relationship between Prelude Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Prelude Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out Prelude Therapeutics Correlation, Prelude Therapeutics Volatility and Prelude Therapeutics Alpha and Beta module to complement your research on Prelude Therapeutics. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Prelude Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.